Skip to main content
Equibles
VERA logo

VERA · Vera Therapeutics, Inc. · Financials

Track VERA — free

Use VERA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VERA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$35.05 +1.45 (+4.32%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$2.47B
Shares
72.06M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Net Income
-$299.62M -96.9%
FY2025 Net Income FY2020–FY2025
Diluted EPS
-$4.66 -69.5%
FY2025 Diluted EPS FY2021–FY2025
Operating Cash Flow
-$241.1M -79%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
$261.87M $215.26M $126.17M $78.23M $68.99M $22.48M $45.21M
$153.89M $100.22M $41M $23.79M $21.91M $11.92M $4.04M
$536K $468K $105K $21K -$846K $176K $251K
— — — — — $0 $3M
$415.76M $315.47M $167.17M $102.01M $90.9M $34.4M $52.24M
-$415.76M -$315.47M -$167.17M -$102.01M -$90.9M -$34.4M -$52.24M
$7.54M $7.53M $7.63M $3.79M $992K $20K $166K
$22.96M $24.48M $20.71M $7.98M $1.75M $15K $8000
$13.87M $15.86M $15.02M $6.02M $1.85M $1.79M -$1.17M
— -$299.61M -$152.15M -$95.99M -$89.06M -$32.61M -$53.41M
— $1000 $1000 $1000 $1000 $1000 -$1000
-$401.9M -$299.62M -$152.15M -$95.99M -$89.06M -$32.61M -$53.41M
USD/shares -$5.86 -$4.66 -$2.75 -$2.25 -$3.35 -$2.43 —
USD/shares -$5.86 -$4.66 -$2.75 -$2.25 -$3.35 -$2.43 —
shares — 64.23M 55.33M 42.71M 26.57M 13.44M 319.96K
shares — 64.23M 55.33M 42.71M 26.57M 13.44M 319.96K
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $13K in buybacks.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 8.44×
EV/EBIT
—
Peer median 16.46×
P/E (TTM)
—
Peer median 17.63×

Peer medians compare against the 242 similar-size Biotechnology companies (of 536 listed).

Key facts CIK 1831828 CUSIP 92337R101 13F (30d) 132 filings 132 filers Visit website Investor relations